GCF2033

GCF2033 is a small molecule therapeutic candidate being developed by Guangzhou Green Cross Pharmaceutical for the treatment of premenstrual syndrome (PMS). It is classified as a Class 2.3 chemical drug in China, which refers to a modified new drug formulation—such as a new dosage form, strength, or route of administration—that demonstrates clinical advantages over existing therapies. As of 2024, the program is in the preclinical stage, specifically undergoing Chemistry, Manufacturing, and Controls (CMC) development. While the specific active ingredient has not been formally disclosed in the pipeline, the company's broader portfolio includes formulations of selective serotonin reuptake inhibitors (SSRIs) for related neuropsychiatric conditions.